Here's What Top Pharma Execs Expect Under Donald Trump

One CEO said the industry needs to police itself or face government repercussions.

Top executives from large U.S. drugmakers on Thursday discussed for the first time possible changes for the industry under President-elect Donald Trump, and issues that have damaged the reputation of their industry.

Since he was elected, Trump, who has said he wants to repeal Obamacare and reform Medicare and Medicaid, has not addressed the sharp drug price increases that dominated the Presidential campaign.

Back to news